“EVERLAST-A: A Phase 2a Study Design of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody for Plaque Psoriasis”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s633. https://doi.org/10.25251/jg65bt44.